share_log

微創醫療：海外監管公告

MICROPORT: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Jan 29 07:55
Summary by Moomoo AI
微創醫療科學有限公司（微創醫疗）宣布其持股約40.32%的子公司上海微創心脈醫療科技（心脈醫療科技）於上海證券交易所科創板發布2022年度業績報告。報告顯示，心脈醫療科技2022年實現營業收入約89.65億元，歸屬於母公司所有者的淨利潤約35.69億元。該公司預計2023年營業收入將達到117.44億元至120.13億元，同比增長31%至34%，淨利潤預計將達到47.46億元至49.25億元，同比增長33%至38%。心脈醫療科技的業績增長主要得益於新產品推廣、海外市場銷售增長以及對老年人口增加相關的醫療需求。微創醫療表示，將繼續加大產品研發力度，以應對老齡化帶來的市場機遇。該業績預告未經審計，最終數據將以公司正式披露的經審計後的年度報告為準。
微創醫療科學有限公司（微創醫疗）宣布其持股約40.32%的子公司上海微創心脈醫療科技（心脈醫療科技）於上海證券交易所科創板發布2022年度業績報告。報告顯示，心脈醫療科技2022年實現營業收入約89.65億元，歸屬於母公司所有者的淨利潤約35.69億元。該公司預計2023年營業收入將達到117.44億元至120.13億元，同比增長31%至34%，淨利潤預計將達到47.46億元至49.25億元，同比增長33%至38%。心脈醫療科技的業績增長主要得益於新產品推廣、海外市場銷售增長以及對老年人口增加相關的醫療需求。微創醫療表示，將繼續加大產品研發力度，以應對老齡化帶來的市場機遇。該業績預告未經審計，最終數據將以公司正式披露的經審計後的年度報告為準。
MICROCHUN MEDICAL SCIENCES CO., LTD. (MICROCHUN MEDICAL TECHNOLOGY) ANNOUNCED ITS SUBSIDIARY SHANGHAI MICROCHUN CARDIAC MEDICAL TECHNOLOGY (CARDIAC MEDICAL TECHNOLOGY), WHICH HAS A SHAREHOLDING OF APPROXIMATELY 40.32% ON THE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE, TO RELEASE ITS ANNUAL RESULTS REPORT 2022. Cardiac Medical Technologies achieved sales revenue of approximately $89.65 billion in 2022 and net profit attributable to its parent company owners of approximately $35.69 billion, according to the report. The company expects operating revenue in 2023 to reach $117.44 billion to $120,113 billion, up 31% to 34% year-on-year, and net profit is expected to reach $47.46 million to $49.25 billion, up 33% to 38% year-on-year. Cardiac Medical Technology's performance growth was driven primarily by new product launches, sales growth in overseas markets and the related medical demand for the growing elderly population. MICRO MEDICAL SAID IT WILL CONTINUE TO EXPAND ITS PRODUCT R&D CAPACITY TO ADDRESS THE MARKET OPPORTUNITIES BROUGHT ABOUT BY AGEING. The results announcement is unaudited and the final data will be based on the audited annual report officially disclosed by the company.
MICROCHUN MEDICAL SCIENCES CO., LTD. (MICROCHUN MEDICAL TECHNOLOGY) ANNOUNCED ITS SUBSIDIARY SHANGHAI MICROCHUN CARDIAC MEDICAL TECHNOLOGY (CARDIAC MEDICAL TECHNOLOGY), WHICH HAS A SHAREHOLDING OF APPROXIMATELY 40.32% ON THE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE, TO RELEASE ITS ANNUAL RESULTS REPORT 2022. Cardiac Medical Technologies achieved sales revenue of approximately $89.65 billion in 2022 and net profit attributable to its parent company owners of approximately $35.69 billion, according to the report. The company expects operating revenue in 2023 to reach $117.44 billion to $120,113 billion, up 31% to 34% year-on-year, and net profit is expected to reach $47.46 million to $49.25 billion, up 33% to 38% year-on-year. Cardiac Medical Technology's performance growth was driven primarily by new product launches, sales growth in overseas markets and the related medical demand for the growing elderly population. MICRO MEDICAL SAID IT WILL CONTINUE TO EXPAND ITS PRODUCT R&D CAPACITY TO ADDRESS THE MARKET OPPORTUNITIES BROUGHT ABOUT BY AGEING. The results announcement is unaudited and the final data will be based on the audited annual report officially disclosed by the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more